Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
. 2023 May 11;5(1):vdad061.
doi: 10.1093/noajnl/vdad061. eCollection 2023 Jan-Dec.

Cerebrospinal fluid 2-hydroxyglutarate as a monitoring biomarker for IDH-mutant gliomas

Cecile Riviere-Cazaux  1 , Jean M Lacey  1 , Lucas P Carlstrom  1 , William J Laxen  1 , Amanda Munoz-Casabella  1 , Matthew D Hoplin  1 , Samar Ikram  1 , Abdullah Bin Zubair  1 , Katherine M Andersen  1 , Arthur E Warrington  1 , Paul A Decker  1 , Timothy J Kaufmann  1 , Jian L Campian  1 , Jeanette E Eckel-Passow  1 , Sani H Kizilbash  1 , Silvia Tortorelli  1 , Terry C Burns  1
Affiliations

Cerebrospinal fluid 2-hydroxyglutarate as a monitoring biomarker for IDH-mutant gliomas

Cecile Riviere-Cazaux et al. Neurooncol Adv. .
No abstract available

Keywords: 2-hydroxyglutarate; IDH; biomarker; glioma; monitoring.

PubMed Disclaimer

Conflict of interest statement

None.

Figures

Figure 1.
Figure 1.
D-2-HG and D/L-2-HG decrease with decreasing tumor burden. (A) D-and-L-2-HG were quantified via gas chromatography-mass spectrometry (GC-MS) in cerebrospinal fluid (CSF) samples collected prior to and after resection in 7 patients with IDH1-mutant gliomas based on IDH1-R132H immunostaining, 5 of whom had primary tumors and one of whom had a recurrent glioma (patient 136). The average and standard deviation are shown from 30 intracranial IDH-wild type glioma CSF samples. (B) CSF was obtained from patient 138 (intraventricular grade 4 IDH-mutant astrocytoma) prior to resection and on postoperative days 1 and 2 via an external ventricular drain. CSF was obtained from (C) patient 46 and (D) patient 98 (both grade 4 IDH-mutant astrocytomas) prior to resection and at multiple time points during chemoradiation treatment.
See this image and copyright information in PMC

Update of

References

    1. Kalinina J, Ahn J, Devi NS, et al. . Selective detection of the D-enantiomer of 2-hydroxyglutarate in the CSF of glioma patients with mutated isocitrate dehydrogenase. Clin Cancer Res. 2016;22(24):6256–6265. - PMC - PubMed
    1. Fujita Y, Nunez-Rubiano L, Dono A, et al. . IDH1 p.R132H ctDNA and D-2-hydroxyglutarate as CSF biomarkers in patients with IDH-mutant gliomas. J Neurooncol. 2022;159(2):261–270. - PMC - PubMed
    1. Waitkus MS, Diplas BH, Yan H.. Isocitrate dehydrogenase mutations in gliomas. Neuro Oncol. 2016;18(1):16–26. - PMC - PubMed
    1. Noushmehr H, Weisenberger DJ, Diefes K, et al. ; Cancer Genome Atlas Research Network. Identification of a CpG island methylator phenotype that defines a distinct subgroup of glioma. Cancer Cell. 2010;17(5):510–522. - PMC - PubMed
    1. Gilbert MR, Liu Y, Neltner J, et al. . Autophagy and oxidative stress in gliomas with IDH1 mutations. Acta Neuropathol. 2014;127(2):221–233. - PMC - PubMed

LinkOut - more resources